Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Anything relating to the treatment and therapy available for CML
Post count:
1 112Thread count:
187Machine name:
treating_cmlYou are here
Treating CML
Overview CML 1st line, 2nd line, managing resistance- Michael Mauro
Treatment-free remission, stop trials, predictors for stopping treatment- Andreas Hochhaus
The patient perspective on treatment-free remission, including support needs- Pat Elliott
Panel discussion: The psychology of stopping treatment
Upcoming clinical trials (Michael Mauro)
Beyond TKIs - addressing different pathways (Arnon Nagler)
"Do we all do it in the same way?" EBMT documentary
DASISION
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for CML in chronic phase
